

00270690

CLAIMS

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled;
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)

00270690

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (Cancelled)

45. (Added) Use of isoliquiritigenin in the preparation of a medicine for the therapy and prevention of kidney diseases, liver diseases, or complicated diseases of the kidney and the liver.

46. (Added) Use of isoliquiritigenin according to Claim 45, wherein said diseases are kidney diseases.

47. (Added) Use of isoliquiritigenin according to Claim 46, wherein said kidney diseases are at least one of acute nephritis caused by functional disorders of kidney caused by

60270690

abnormality in the metabolic functions, and chronic nephritis developed from such acute nephritis.

48. (Added) Use of isoliquiritigenin according to Claim 47, wherein said abnormality in the metabolic functions is caused by drugs.

49. (Added) Use of isoliquiritigenin according to Claim 46, wherein said kidney diseases are at least one of a group of functional disorders of the kidney consisting of acute nephritis caused by the intermediary of the immunological mechanism, and chronic nephritis developed from such acute nephritis.

50. (Added) Use of isoliquiritigenin according to Claim 46, wherein said kidney diseases are at least one of a group of functional disorders of the kidney consisting of acute nephritis caused by bacteria and virus infection, and chronic nephritis developed from such acute nephritis.

51. (Added) Use of isoliquiritigenin according to Claim 46, wherein said kidney diseases are functional disorders of at least one kidney portion such as the glomerulus, the renal tubule, or the lupus.

52. (Added) Use of isoliquiritigenin according to Claim 45, wherein said diseases are liver diseases.

53. (Added) Use of isoliquiritigenin according to Claim 52, wherein said liver diseases are functional disorders of the liver caused by abnormality in the metabolic functions and in the biosynthetic functions.

54. (Added) Use of isoliquiritigenin according to Claim 53, wherein said abnormality in the metabolic functions and in

00270690

the biosynthetic function is caused by drugs.

55. (Added) Use of isoliquiritigenin according to Claim 52, wherein said liver diseases are fatty liver or chronic hepatitis developed from fatty liver.

56. (Added) Use of isoliquiritigenin according to Claim 52, wherein said liver diseases are viral hepatitis caused by virus infection or chronic hepatitis developed from such hepatitis.

57. (Added) Use of isoliquiritigenin according to Claim 45, wherein said diseases are complicated diseases of the kidney and the liver.

58. (Added) A method for the therapy and prevention of kidney diseases, liver diseases, or complicated diseases of the kidney and the liver, comprising administering a mammal with a medicine containing a therapeutically or prophylactically effective amount of isoliquiritigenin as an active ingredient.